{"id":31438,"date":"2025-04-09T15:24:50","date_gmt":"2025-04-09T07:24:50","guid":{"rendered":"https:\/\/flcube.com\/?p=31438"},"modified":"2025-04-09T15:24:52","modified_gmt":"2025-04-09T07:24:52","slug":"highlife-sass-tmvr-system-receives-fda-breakthrough-device-designation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31438","title":{"rendered":"HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation"},"content":{"rendered":"\n

Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996<\/a>), announced that it has received Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for its novel trans-septal mitral valve replacement (TMVR) system. This designation highlights the system’s potential in addressing moderate to severe mitral regurgitation (MR), a condition affecting a significant patient population globally.<\/p>\n\n\n\n

Clinical Evaluation<\/strong>
The TMVR system is currently under clinical evaluation in Europe, Asia Pacific, and the US. This innovative solution was exclusively licensed to Peijia Medical for Greater China in December 2020, with the technology transfer successfully completed, marking a significant step in the global development of this promising medical device.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996),…<\/p>\n","protected":false},"author":1,"featured_media":31440,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[34,3981,1161,319],"class_list":["post-31438","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-breakthrough-therapy","tag-highlife-medical","tag-hkg-9996","tag-peijia-medical"],"yoast_head":"\nHighLife SAS's TMVR System Receives FDA Breakthrough Device Designation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996), announced that it has received Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for its novel trans-septal mitral valve replacement (TMVR) system. This designation highlights the system's potential in addressing moderate to severe mitral regurgitation (MR), a condition affecting a significant patient population globally.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31438\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighLife SAS's TMVR System Receives FDA Breakthrough Device Designation\" \/>\n<meta property=\"og:description\" content=\"Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996), announced that it has received Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for its novel trans-septal mitral valve replacement (TMVR) system. This designation highlights the system's potential in addressing moderate to severe mitral regurgitation (MR), a condition affecting a significant patient population globally.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31438\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T07:24:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-09T07:24:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0904-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation\",\"datePublished\":\"2025-04-09T07:24:50+00:00\",\"dateModified\":\"2025-04-09T07:24:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438\"},\"wordCount\":127,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0904-png.webp\",\"keywords\":[\"Breakthrough therapy\",\"HighLife Medical\",\"HKG: 9996\",\"Peijia Medical\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31438#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31438\",\"name\":\"HighLife SAS's TMVR System Receives FDA Breakthrough Device Designation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0904-png.webp\",\"datePublished\":\"2025-04-09T07:24:50+00:00\",\"dateModified\":\"2025-04-09T07:24:52+00:00\",\"description\":\"Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996), announced that it has received Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for its novel trans-septal mitral valve replacement (TMVR) system. This designation highlights the system's potential in addressing moderate to severe mitral regurgitation (MR), a condition affecting a significant patient population globally.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31438\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0904-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0904-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"HighLife SAS's TMVR System Receives FDA Breakthrough Device Designation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31438#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HighLife SAS's TMVR System Receives FDA Breakthrough Device Designation - Insight, China's Pharmaceutical Industry","description":"Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996), announced that it has received Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for its novel trans-septal mitral valve replacement (TMVR) system. This designation highlights the system's potential in addressing moderate to severe mitral regurgitation (MR), a condition affecting a significant patient population globally.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31438","og_locale":"en_US","og_type":"article","og_title":"HighLife SAS's TMVR System Receives FDA Breakthrough Device Designation","og_description":"Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996), announced that it has received Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for its novel trans-septal mitral valve replacement (TMVR) system. This designation highlights the system's potential in addressing moderate to severe mitral regurgitation (MR), a condition affecting a significant patient population globally.","og_url":"https:\/\/flcube.com\/?p=31438","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-09T07:24:50+00:00","article_modified_time":"2025-04-09T07:24:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0904-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31438#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31438"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation","datePublished":"2025-04-09T07:24:50+00:00","dateModified":"2025-04-09T07:24:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31438"},"wordCount":127,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31438#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0904-png.webp","keywords":["Breakthrough therapy","HighLife Medical","HKG: 9996","Peijia Medical"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31438#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31438","url":"https:\/\/flcube.com\/?p=31438","name":"HighLife SAS's TMVR System Receives FDA Breakthrough Device Designation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31438#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31438#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0904-png.webp","datePublished":"2025-04-09T07:24:50+00:00","dateModified":"2025-04-09T07:24:52+00:00","description":"Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996), announced that it has received Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for its novel trans-septal mitral valve replacement (TMVR) system. This designation highlights the system's potential in addressing moderate to severe mitral regurgitation (MR), a condition affecting a significant patient population globally.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31438#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31438"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31438#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0904-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0904-png.webp","width":1080,"height":608,"caption":"HighLife SAS's TMVR System Receives FDA Breakthrough Device Designation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31438#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0904-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31438"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31438\/revisions"}],"predecessor-version":[{"id":31441,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31438\/revisions\/31441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31440"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}